SYN008 (omalizumab biosimilar)
/ Synermore, CSPC Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 06, 2025
Equivalence of SYN008 versus omalizumab in patients with refractory chronic spontaneous urticaria: A multicenter, randomized, double-blind, parallel-group, active-controlled phase III study.
(PubMed, Chin Med J (Engl))
- No abstract available
Clinical • Journal • P3 data • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria
August 18, 2021
A study to compare SYN008 and Xolair for the treatment of chronic urticaria not well controlled by antihistamines
(clinicaltrialsregister.eu)
- P3; N=480; Ongoing; Sponsor: Synermore Biologics Co., Ltd
Clinical • New P3 trial • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Chronic Spontaneous Urticaria • Dermatology • Immunology • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis • Urticaria • PCR
1 to 2
Of
2
Go to page
1